logo
logo

RevOpsis Therapeutics secured $16.5 million in seed funding to develop and commercialize treatments for neovascular AMD

RevOpsis Therapeutics secured $16.5 million in seed funding to develop and commercialize treatments for neovascular AMD

04/25/24, 1:37 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgspringfield
Money raised
$16.5 million
Industry
biotechnology
Round Type
seed
Investors
Several Leading Retina Specialists, Various Private And Angel Investors, Ophthalmic Drug And Device Development Firm, Leading Contract Development And Manufacturing Organization (Cdmo)
RevOpsis Therapeutics has successfully closed its first seed funding round, raising $16.5 million. The funding will propel its mission to develop and commercialize treatments for chronic multifactorial diseases through the company's proprietary Rev-Mod Platform.

Company Info

Company
RevOpsis Therapeutics
Location
springfield, illinois, united states
Additional Info
RevOpsis Therapeutics is a next-generation biopharmaceutical company that is trailblazing a new era in multispecific antibody discovery and development to unlock transformative treatments for complex disease.

Related People